Company intelligence / Profile preview

Huayin Medicine

Guangzhou, Guangdong, Chinahuayinlab.com ↗

Ownership: Private
Development stage: Commercial

Overview

Huayin Medicine specializes in R&D, production, and service of molecular diagnostic products including RT-PCR and ELISA kits. The company has developed over two hundred TaqMan PCR diagnostic kits—11 of which have received Certificates and Manufacture Approvals from the Chinese FDA. It was the first to receive approval for an FQ-PCR-based influenza A/B test kit in China. Their COVID‑19 RT-PCR detection kits are widely used domestically and internationally.

Therapeutic areas: Infectious Diseases
Modalities: Diagnostic kit (RT-PCR)ELISA diagnostic kitMolecular diagnostic techniques
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Huayin Medicine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Huayin Medicine.

Explore the full profile